NANO Nanobiotix SA

NANOBIOTIX to Participate in Investor Conferences in March

NANOBIOTIX to Participate in Investor Conferences in March

PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in these upcoming conferences in March:

TD Cowen's Health Care Conference

Date: Wednesday, March 4, 2026

Location: Boston, MA

Time of the fireside chat: 11:10am ET / 5:10pm CET

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

UBS Biotech Summit Miami

Date: Monday, March 9, 2026

Location: Miami Beach, FL

Jefferies Biotech on the Beach Summit

Date: Tuesday, March 10, 2026

Location: Miami Beach, FL

Leerink's Global Healthcare Conference

Date: Wednesday, March 11, 2026

Location: Miami Beach, FL

Time of the fireside chat: 2:20pm EDT / 7:20pm CET

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at or follow us on and .

Contacts

Nanobiotix
Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

Investor Relations Department



Joanne Choi

VP, Investor Relations (US)

+1 (713) 609-3150



Ricky Bhajun

Director, Investor Relations (EU)

+33 (0) 79 97 29 99







Media Relations


France – HARDY

Caroline Hardy

50







Global – uncapped

Becky Lauer

+1 (646) 286-0057

  

  Attachment



EN
25/02/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
 PRESS RELEASE

NANOBIOTIX Announces Presentation of First Data from a Randomized Phas...

NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of first data from the CONVERGE study, a Johnson...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch